In RA patients, biventricular systo-diastolic function of the heart was impaired compared to FM (Table 2) . Over the study-period, myocardial function improved (Table 2 ) and DAS28-CRP declined (3.5±1.1 vs 2.3±1.0; p<0.001). Only RA patients had LGE, with no improvement over time (67%). Background: Longitudinal studies of the carotid intima-media thickness (IMT) change in RA suggested a role for inflammation in atherosclerosis progression. However, data on well controlled joint disease are scarce since most studies enrolled patients with very high disease activity. Objectives: To estimate atherosclerosis progression and identify influencing factors in a cohort of longstanding and well controlled RA patients. Methods: One hundred nine RA patients (females 80%, age 59±12 years, disease duration 15.6±10.6 years, mean Framingham 10-year CV disease risk score 16±12%) without previous cardiovascular (CV) events underwent carotid ultrasound (CUS) examination at baseline and after a mean time of 1.1±0.3 years. Atheromatous plaques and intima-media thickness (IMT) were assessed. Data on CV risk factors, inflammation markers, medications, and RA characteristics were collected. Results: Overall, we observed a significant increase of IMT (0.03±0.10 mm, p=0.005) and plaques (+ 8%, p=0.035). The IMT progression rate was 0.027 mm/year (95% CI 0.007 -0.046). Disease activity (DAS28-CRP) remained stable (2.68±1.01 vs 2.79±1.33, p=0.45). Anti-rheumatic, cardiovascular medications and the number of CV risk factors were substantially unchanged. In models of regression analysis sex, age, dyslipidemia, hypertension and use of corticosteroids were independently associated with the increase of IMT, whereas there were no confounding from use of biological therapies, seropositivity or disease duration. Patients with active disease (DAS28-CRP ≥2.6) had a significant increase in IMT (0.04±0.11 mm, p=0.009). Conversely, there was not a significant progression of patients in remission, who had also a lower prevalence of hypertension (40% vs 64%, p=0.027), dyslipidemia (43% vs 58%, p=0.044), and use of corticosteroids (37% vs 63%, p=0.007) and were receiving more frequently methotrexate (60% vs 40%, p=0.027).
Conclusions:
In patients with established and controlled RA, the progression of atherosclerosis is mainly driven by traditional CV risk factors than disease activity. In addition, a remission state is associated with a lower prevalence of CV risk factors, which in turn could account for a slower progression of atherosclerosis in these patients. This study provides evidence that even in RA patients who achieve good disease control the treatment of CV risk factors should be optimized. Background: Rheumatoid arthritis (RA) is characterised by joint inflammation, resulting in functional impairment. Consequently, it has long been recognised that work disability is common in RA. However, despite significant pharmacological advances in disease control, little is known about contemporary impact upon work. Depression has emerged in recent years as a key comorbidity in RA. In the general population, depression is strongly correlated with work disability Objectives: To establish the extent to which depression associates with work ability in RA in a cross sectional study. Methods: Our hospital routinely collects data via an electronic screening interface, which incorporates a series of validated questionnaires, which patients complete via an iPad while waiting for their appointment. The dataset is linked to the clinical record. For this study, cross sectional data were extracted on adults with RA. Question 2 of the Work and Social Adjustment Scale ("Because of my [RA] my ability to work is impaired") was used as a measure or work disability (scale 0-8). Mental health status was collected using the Patient Health Questionnaire-2 (PHQ), with a score≥3 considered a positive screen for depression. 
Background:
In the general population, polypharmacy (PP) is associated with increased risk of adverse events. The relationship between adverse outcomes and PP in Rheumatoid Arthritis (RA) has not been studied in depth. The mantra of treatment in RA encourages PP through combination Disease Modifying Anti-Rheumatic Drugs (DMARD). Objectives: To study the relationship between PP and serious adverse events in RA, including the influence of DMARDs within the PP count. Methods: Data from the British Society for Rheumatology Biologics Register were analysed. PP was defined as number of drugs co-prescribed at baseline, with two models: (1) including DMARDs (2) excluding DMARDs from the medication count. PP was stratified by 0-5, 6-9 and >10. Patients were studied from initiation of 1st biologic until 1st serious adverse event (SAE), 3 years of follow up, or last available visit, whichever came first. A Cox-proportional hazard model was used, with adjustment for a priori selected cofounders. Results: This study included 15,004 patients commencing biologics. The demographics are shown in table 1. Excluding DMARDs from the PP cohort, 7,115 (47%) of the patients were taking up to 5 drugs; 6,010 (40%) were taking 6 to 9 drugs; 1,870 (12%) were taking 10 or more medications. Higher levels of PP associated with older age, more severe disease, and longer disease duration. PP predictably associated with comorbidities; the relationship was not linear: comorbidity count appeared to show a ceiling effect. The overall incidence of SAEs was 25.5/100 person years (95% CI 24.7-26.3). The rate of SAEs increased across the PP counts (See Table 1 ). The relationship remained significant after adjusting for comorbidities. Including DMARDs within the PP count attenuated the association. Conclusions: PP is common in patients with RA and is associated with adverse outcomes especially when patients are on >10 drugs. Including or excluding DMARDs from the PP model had negligible impact on findings. The relationship between PP and comorbidity is worthy of further research, as PP represents a potentially simple but valuable predictor of adverse outcomes, and a suitable surrogate for comorbidity in epidemiological analyses. Background: Insulin resistance (IR) is a comorbidity found in about 40%of RA patients. Currently, there is little information regarding the role of antibodies against citrullinated proteins and IR development in RA. Patients positive for ACPA and/or RF may be at higher risk of IR since these group of patients has a higher expression pro-inflammatory citokines like TNFa and IL-6, both implicated in the pathogenesis of IR. Objectives: To analyze the contribution of autoantibodies positivity (ACPA and/or RF) and their impact in the development of IR in patients with RA. Methods: We retrospectively analyzed patients classified with RA per ACR 1987 and ACR/EULAR 2010 criteria with at least one year of follow-up in a cohort of RA patients without comorbidities from Hospital Civil "Juan I. Menchaca". DAS-28, basal insulin, HOMA-IR and anthropometric parameters: Body weight, body mass index (BMI), Sum 4 skinfold thicknesses (S4T), Waist to hip ratio (WHR), waist circumference (WC) and total fat mass (FM); were determined at current and baseline. Mean differences between the two time points were calculated. A multiple regression model was constructed considering mean insulin change as dependent variable. Results: We studied 57 RA patients, 44% (25) with IR and 56% (32) without IR. Of these, 21% (12) developed IR during follow-up. BMI, FM and ST4 were higher at baseline in patients with current IR at baseline. Ptients who developed IR during follow-up had a mean increase of DAS-28 of 1.27 (P<0.005 vs. patients who improved or never developed IR). Patients positive for ACPA had a greater increase in IR during follow-up. Multivariate analysis revealed that ACPA, increments in WHR and ST4 were independent predictors of basal insulin increases during follow-up. Objectives: To analyze the prophylactic effect of TMP-SMX against severe bacterial infections in elderly patients with rheumatoid arthritis undergoing treatment with biologics. Methods: Data were retrospectively collected from the medical records of patients with rheumatoid arthritis at our center. We divided the elderly patients (65 years or above) who took biologic agents into two groups. The first group (TMP-SMX+) comprised patients who previously or concurrently started TMP-SMX with biologic
